Citable filing context

ZTS filing events and research context

Server-rendered

ZTS's research view summarizes recent SEC filing context, starting with mda_quarterly from May 7, 2026.

ZTS filing events and research context
FiledItemContext
May 7, 2026mda_quarterlyZoetis reported Q1 2026 revenue of $2,262 million, a 3% increase year-over-year, though operational revenue declined by 1%. This operational contraction resulted from a 3% volume decrease in key franchises and the impact of the medicated feed additive (MFA) divestiture, partially offset by 2% price growth. The U.S. segment revenue fell 8%, driven by softer demand and heightened competition in the companion animal dermatology franchise, specifically regarding Simparica Trio and generic competition for Convenia and Cerenia. In contrast, the International segment revenue rose 17%, with 9% operational growth fueled by Simparica Trio, vaccines, and livestock demand in cattle, swine, and poultry. Foreign exchange provided a 4% tailwind to reported revenue. Key risks include potential tariffs impacting trade with China and the EU, animal disease outbreaks affecting livestock markets, and competitive pressures in the companion animal space. Management is also navigating a fiscal year alignment for international subsidiaries and a transition to a new ERP system. The company continues to utilize its $6 billion share repurchase authorization and maintains liquidity through a $1.3 billion revolving credit facility and a recent $2 billion convertible senior notes offering.
Feb 12, 2026businessZoetis is a global leader in animal health, serving companion animals and livestock across more than 100 countries. In 2025, total revenue reached $9.467 billion, with companion animal products contributing $6.587 billion and livestock contributing $2.764 billion. Revenue is highly concentrated; Simparica/Simparica Trio and Apoquel/Apoquel Chewable alone account for 28% of total sales. The company is prioritizing growth through R&D in diagnostics, genetics, and digital data analytics. Key financial risks include significant foreign exchange exposure, as 42% of revenue is denominated in foreign currencies, and potential margin compression resulting from a shift in companion animal distribution from veterinarians to e-commerce and big-box retailers. In the livestock sector, Zoetis faces headwinds from government restrictions on antibacterials due to resistance concerns and the volatility of animal disease outbreaks. Manufacturing risks are elevated due to complex, sole-sourced processes and potential capacity imbalances. Recent strategic activity includes the divestiture of the medicated feed additive portfolio. While current growth is supported by pricing power and lifecycle innovation, results remain sensitive to weather patterns and climate-related impacts on livestock productivity and aquaculture.
Feb 12, 2026mdaZoetis reported 2025 revenue of $9.47 billion, a 2% increase, and net income of $2.67 billion, up 8%. Operational revenue growth of 3% was driven by 4% price increases, partially offset by the divestiture of the medicated feed additive portfolio. Companion animal revenue grew 5% to $6.59 billion, while livestock revenue fell 5% to $2.76 billion. Simparica/Simparica Trio and Apoquel/Apoquel Chewable remain critical drivers, contributing 16% and 12% of total revenue, respectively. However, generic competition poses a significant risk, highlighted by a 66% decline in U.S. sales for Draxxin since 2021. Analysts should note the trend toward e-commerce and big-box retail distribution for companion animal products, which may pressure long-term margins. In the livestock sector, regulatory restrictions on antibacterials and disease outbreaks are primary headwinds. To support capital returns, Zoetis spent $3.2 billion on share repurchases in 2025, funded in part by a $2 billion convertible senior note offering and a new $1.25 billion revolving credit facility. Additionally, the company is implementing a global ERP transition to eliminate a one-month reporting lag for international subsidiaries by 2026.

Source: SEC EDGAR filing text and events; period May 7, 2026; filed May 7, 2026.

Continue research

Keep researching ZTS

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →